Amylyx Pharmaceuticals, Inc. Common Stock
AMLX US03237H1014
United States 02141
MA CAMBRIDGE 43 THORNDIKE STREET
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Founded 2013
https://www.amylyx.com/
https://en.wikipedia.org/wiki/Amylyx_Pharmaceuticals
Annual Performance 1
| 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|
| 104% | -59% | -75% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Transactions: 38 Insiders: 10
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Mazzariello Gina |
8.34 USD |
15,000 Sold |
125,046 USD |
12/08/2025 | 13/08/2025 |
| Mazzariello Gina |
8.07 USD |
15,000 Sold |
121,103 USD |
12/08/2025 | 12/08/2025 |
| Mazzariello Gina |
3.48 USD |
9,192 Sold |
31,954 USD |
31/03/2025 | 31/03/2025 |
| Bedrosian Camille L |
3.47 USD |
12,425 Sold |
43,082 USD |
31/03/2025 | 31/03/2025 |
| Klee Justin B. |
3.46 USD |
21,490 Sold |
74,454 USD |
31/03/2025 | 31/03/2025 |
| Cohen Joshua B |
3.47 USD |
21,490 Sold |
74,482 USD |
31/03/2025 | 31/03/2025 |
| Frates James M |
3.47 USD |
10,896 Sold |
37,806 USD |
31/03/2025 | 31/03/2025 |
| Zeiher Bernhardt G |
3.70 USD |
10,000 Bought |
37,005 USD |
20/03/2025 | 20/03/2025 |
| Cohen Joshua B |
3.17 USD |
4,595 Sold |
14,549 USD |
03/03/2025 | 03/03/2025 |
| Klee Justin B. |
3.15 USD |
4,595 Sold |
14,483 USD |
03/03/2025 | 03/03/2025 |